alnylam
A Scientist in Analytical Sciences drives the development and implementation of innovative portfolio-based analytical technologies for the impurity characterization of siRNA therapeutics. This role involves collaborating with stability sciences, process development, and early development teams to define analytical strategies and execute forced degradation studies. The position requires utilizing advanced analytical platforms to support full lifecycle impurity profiling and regulatory documentation for new development candidates.
Headquarters
Cambridge, Massachusetts, United States
Company Size
1001-5000 employees
Founded
2002
Alnylam is a biopharmaceutical company that has pioneered RNA interference (RNAi) therapeutics, an innovative class of medicines that treats diseases by silencing the genes that cause or contribute to them. The company develops RNAi-based medicines targeting both rare and prevalent diseases across multiple therapeutic areas, with approved products and a robust investigational pipeline. Driven by science and inspired by patients, Alnylam is committed to delivering transformational medicines that address diseases at their genetic source.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for alnylam.
14% above the average for this role
Senior Scientist I, Analytical Chemistry
AbbVie
Principal Scientist, Analytical Development
Bristol Myers Squibb
Scientist
Pace® Analytical Services
Executive - Analytical Development
Sun Pharmaceutical Industries Limited
Associate Scientist - Analytical & Bioanalytical Mass Spectrometry (ABMS)
Regeneron Pharmaceuticals
Temporary Staff Analytical Chemist
Vir Biotechnology